New epilepsy drug shows promise in Long-Term safety trial
Disease control
Recruiting now
This study tests an investigational drug called CB03-154 in 144 people with focal epilepsy. Participants take the drug for up to two years to see if it is safe and helps reduce seizures. The goal is to find a better long-term treatment option for epilepsy.
Phase: PHASE2 • Sponsor: Shanghai Zhimeng Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC